News and Announcements

AstraZeneca asthma drug fails to meet end goal in COPD trials

By Abigail Townsend

Date: Wednesday 17 Sep 2025

(Sharecast News) - AstraZeneca said on Monday that asthma drug Fasenra had failed to meet core targets in trials involving patients with severe lung disease.
The drugs giant said phase III trials into Fasenra, which is already approved as an add-on maintenance treatment for severe eosinophilic asthma, had shown numerical improvement.

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page